Get the Stockscreener App
11.15
4.11%
0.44
Nuvectis Pharma Inc stock is traded at $11.15, with a volume of 76,186.
It is up +4.11% in the last 24 hours and up +1.00% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$10.71
Open:
$10.94
24h Volume:
76,186
Relative Volume:
0.96
Market Cap:
$295.76M
Revenue:
-
Net Income/Loss:
$-29.59M
P/E Ratio:
-8.7451
EPS:
-1.275
Net Cash Flow:
$-18.35M
1W Performance:
+18.37%
1M Performance:
+1.00%
6M Performance:
+45.75%
1Y Performance:
+32.58%
1-Day Range:
$10.73
$11.23
1-Week Range:
$9.3501
$11.23
52-Week Range:
$5.55
$13.34
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
11.15 | 295.76M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
NVCT Q1 2026 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue StatusRevenue Per Share - newsline.com
NVCT Maintained by HC Wainwright & Co. -- Price Target Raised to $13.00 - GuruFocus
Nuvectis Shareholders Approve Director Election and Auditor Ratification - TipRanks
Nuvectis Pharma (NVCT) director granted 35,000 restricted common shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted shares, now holds 122,828 - Stock Titan
Nuvectis Pharma (NVCT) grants director Juan Sanchez 35,000 restricted shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted common shares in Form 4 filing - Stock Titan
[8-K] Nuvectis Pharma, Inc. Reports Material Event - Stock Titan
Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright - TipRanks
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Cost DisciplinePost-Earnings Reaction - newsline.com
Nuvectis Pharma (NVCT) Rallies 1.94% as Stock Tests Key Resistance at $11.04Long Short Pair - newsline.com
Analyst Reiterates Buy on Nuvectis Pharma, Maintains $17 Price Target on NXP900 Pipeline Upside and Favorable M&A Read‑Through - TipRanks
(NVCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances PipelineProfit Inflection Point - newsline.com
NVCT Q1 2026 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Analysis - newsline.com
Responsive Playbooks and the NVCT Inflection - Stock Traders Daily
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesSlow Growth Warning - The Legal Advocate
Nuvectis Pharma (NVCT) Declines 5.39% as Stock Tests Key Support LevelIchimoku Cloud - thelegaladvocate.com
Wall Street analysts think Nuvectis Pharma (NVCT) could surge 57%: Read this before placing a bet - MSN
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet - sharewise.com
NVCT Q1 2026 Earnings: Better-than-Expected Loss Narrower as Company Advances PipelineRevenue Growth Outlook - newsline.com
Nuvectis Pharma (NVCT) Surges +2.82%, Nearing $11.48 Resistance 2026-05-21IV Contraction - Newser
Understanding the Setup: (NVCT) and Scalable Risk - Stock Traders Daily
NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma set to participate in key investor event at NASDAQ - Traders Union
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor ... - Caledonian Record
Number of shareholders of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Number of shareholders of Nuvectis Pharma, Inc. – BOATS:NVCT - TradingView
TradingKey - TradingKey
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN
The Technical Signals Behind (NVCT) That Institutions Follow - Stock Traders Daily
What Nuvectis Pharma (NVCT) does that creates lasting value (Creeps Higher) 2026-05-08Momentum Investing - newser.com
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvectis Pharma | 10-Q: Q1 2026 Earnings Report - Moomoo
Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary - TradingView
Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsSEC.gov - SEC.gov
Nuvectis Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvectis Pharma posts first quarter 2026 financial results and business update - Traders Union
Cancer drug developer targets summer data as cash drops to $25.1M - Stock Titan
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma - Yahoo Finance
NVCT (Nuvectis Pharma) posts narrow Q4 2025 EPS miss, edging down 0.23% in muted investor reaction.Open Stock Picks - newser.com
Nuvectis Pharma Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
NVCT Forecast, Price Target & Analyst Ratings | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma (NVCT) Stock: Technical Risk Signals | Q4 2025: Below ExpectationsCommunity Risk Signals - Newser
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):